Literature DB >> 1093106

Nocardiosis in children: report of three cases and review of the literature.

Z H Idriss, R J Cunningham, C M Wilfert.   

Abstract

The clinical illnesses observed in three adolescents with Nocardia asteroides infection are described. The organism has been classified as a bacterium and placed in the Actinomycetaceae family. Sulfonamides remain the first choice for chemotherapy but alternative drugs are available and may be essential in successful therapy. Nocardial infections in children indicate the need for evaluation for an underlying immunological deficiency. Nocardia species should be considered as possible causative agents in immunocompromised patients with infection.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1093106

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

Review 1.  Clinical and clinical laboratory aspects of nocardial infection.

Authors:  D A Stevens
Journal:  J Hyg (Lond)       Date:  1983-12

2.  Abdominal nocardiosis in a Sudanese girl.

Authors:  S A Salfield; B I Duerden; J A Dickson; R D Milner
Journal:  Eur J Pediatr       Date:  1983-04       Impact factor: 3.183

Review 3.  Nocardia species: host-parasite relationships.

Authors:  B L Beaman; L Beaman
Journal:  Clin Microbiol Rev       Date:  1994-04       Impact factor: 26.132

4.  Pulmonary nocardiosis manifested as miliary nodules in a neonate--a case report.

Authors:  O H Kim; H R Yang; Y W Bahk
Journal:  Pediatr Radiol       Date:  1992

5.  Effects of activated macrophages on Nacardia asteroides.

Authors:  G A Filice; B L Beaman; J S Remington
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

6.  Actinomyces and nocardia infections in chronic granulomatous disease.

Authors:  Shahindokht Bassiri-Jahromi; Aida Doostkam
Journal:  J Glob Infect Dis       Date:  2011-10

7.  Cervicofacial nocardiosis in children.

Authors:  R M Lampe; C J Baker; E J Septimus; R J Wallace
Journal:  J Pediatr       Date:  1981-10       Impact factor: 4.406

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.